Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Offit

Showing results (141-150 of 429) with videos related to

Pageof 43
Sort By:
Breast Cancer Research and Treatment|February 6, 2013
Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?Steven A Narod, Kelly Metcalfe, Henry T Lynch, et al.
Nature Genetics|March 17, 2009
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasmsOuti Kilpivaara, Semanti Mukherjee, Alison M Schram, et al.
Breast Cancer Research and Treatment|May 15, 2014
Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer familiesAngela G Arnold, Ebunoluwa Otegbeye, Megan Harlan Fleischut, et al.
The Lancet. Oncology|January 2, 2007
Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control studyJohn R McLaughlin, Harvey A Risch, Jan Lubinski, et al.
JAMA|September 28, 2006
Prediction of germline mutations and cancer risk in the Lynch syndromeSining Chen, Wenyi Wang, Shing Lee, et al.
Familial Cancer|October 7, 2022
Barriers to completion of cascade genetic testing: how can we improve the uptake of testing for hereditary breast and ovarian cancer syndrome?Ryan Matthew Kahn, Muhammad Danyal Ahsan, Eloise Chapman-Davis, et al.
BMC Medical Genomics|May 21, 2017
Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testingDonavan T Cheng, Meera Prasad, Yvonne Chekaluk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 2020
Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based ScreeningKenneth Offit, Kaitlyn A Tkachuk, Zsofia K Stadler, et al.
Human Molecular Genetics|March 22, 2021
Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genesRosalie Griffin Waller, Robert J Klein, Joseph Vijai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2010
Susceptibility loci associated with prostate cancer progression and mortalityDavid J Gallagher, Joseph Vijai, Angel M Cronin, et al.
Pageof 43

Showing results (141-150 of 429) with videos related to

Sort By:
Pageof 43
Breast Cancer Research and Treatment|February 6, 2013
Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?Steven A Narod, Kelly Metcalfe, Henry T Lynch, et al.
Nature Genetics|March 17, 2009
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasmsOuti Kilpivaara, Semanti Mukherjee, Alison M Schram, et al.
Breast Cancer Research and Treatment|May 15, 2014
Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer familiesAngela G Arnold, Ebunoluwa Otegbeye, Megan Harlan Fleischut, et al.
The Lancet. Oncology|January 2, 2007
Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control studyJohn R McLaughlin, Harvey A Risch, Jan Lubinski, et al.
JAMA|September 28, 2006
Prediction of germline mutations and cancer risk in the Lynch syndromeSining Chen, Wenyi Wang, Shing Lee, et al.
Familial Cancer|October 7, 2022
Barriers to completion of cascade genetic testing: how can we improve the uptake of testing for hereditary breast and ovarian cancer syndrome?Ryan Matthew Kahn, Muhammad Danyal Ahsan, Eloise Chapman-Davis, et al.
BMC Medical Genomics|May 21, 2017
Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testingDonavan T Cheng, Meera Prasad, Yvonne Chekaluk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 2020
Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based ScreeningKenneth Offit, Kaitlyn A Tkachuk, Zsofia K Stadler, et al.
Human Molecular Genetics|March 22, 2021
Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genesRosalie Griffin Waller, Robert J Klein, Joseph Vijai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2010
Susceptibility loci associated with prostate cancer progression and mortalityDavid J Gallagher, Joseph Vijai, Angel M Cronin, et al.
Pageof 43